Abstract
Purpose
Activation of MET oncogene as the result of amplification or activation mutation represents an emerging molecular target for cancer treatment. We comprehensively studied MET alterations and the clinicopathologic correlations in a large cohort of treatment-naïve non-small cell lung carcinoma (NSCLC).Experimental design
Six hundred eighty-seven NSCLCs were tested for MET exon 14 splicing site mutation (METΔ14), DNA copy number alterations, and protein expression by Sanger sequencing, FISH, and IHC, respectively.Results
METΔ14 mutation was detected in 2.62% (18/687) of NSCLC. The mutation rates were 2.6% in adenocarcinoma, 4.8% in adenosquamous carcinoma, and 31.8% in sarcomatoid carcinoma. METΔ14 mutation was not detected in squamous cell carcinoma, large cell carcinoma, and lymphoepithelioma-like carcinoma but significantly enriched in sarcomatoid carcinoma (P < 0.001). METΔ14 occurred mutually exclusively with known driver mutations but tended to coexist with MET amplification or copy number gain (P < 0.001). Low-level MET amplification and polysomy might occur in the background of EGFR or KRAS mutation whereas high-level amplification (MET/CEP7 ratio ≥5) was mutually exclusive to the major driver genes except METΔ14. Oncogenic METΔ14 mutation and/or high-level amplification occurred in a total of 3.3% (23/687) of NSCLC and associated with higher MET protein expression. METΔ14 occurred more frequently in older patients whereas amplification was more common in ever-smokers. Both METΔ14 and high-level amplification were independent prognostic factors that predicted poorer survival by multivariable analysis.Conclusions
The high incidence of METΔ14 mutation in sarcomatoid carcinoma suggested that MET inhibition might benefit this specific subgroup of patients. Clin Cancer Res; 22(12); 3048-56. ©2016 AACRSee related commentary by Drilon, p. 2832.Full text links
Read article at publisher's site: https://doi.org/10.1158/1078-0432.ccr-15-2061
Read article for free, from open access legal sources, via Unpaywall: https://clincancerres.aacrjournals.org/content/clincanres/22/12/3048.full.pdf
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Discovery of <i>N</i>-substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer.
RSC Med Chem, 03 Oct 2024
Cited by: 0 articles | PMID: 39512947 | PMCID: PMC11539002
Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data.
Ther Adv Med Oncol, 16:17588359241279715, 25 Sep 2024
Cited by: 0 articles | PMID: 39371619 | PMCID: PMC11452854
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions.
Cancers (Basel), 16(16):2882, 19 Aug 2024
Cited by: 0 articles | PMID: 39199653 | PMCID: PMC11352260
Review Free full text in Europe PMC
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
ESMO Open, 9(9):103680, 29 Aug 2024
Cited by: 0 articles | PMID: 39214048 | PMCID: PMC11402035
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.
Ther Adv Med Oncol, 16:17588359241264730, 31 Jul 2024
Cited by: 0 articles | PMID: 39091606 | PMCID: PMC11292687
Go to all (228) article citations
Data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Clin Transl Oncol, 20(7):881-888, 14 Nov 2017
Cited by: 8 articles | PMID: 29139039
High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
J Thorac Oncol, 5(3):305-313, 01 Mar 2010
Cited by: 123 articles | PMID: 20107422
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
J Thorac Oncol, 4(1):12-21, 01 Jan 2009
Cited by: 51 articles | PMID: 19096301
[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
Rev Mal Respir, 35(8):796-812, 31 Aug 2018
Cited by: 5 articles | PMID: 30174236
Review